In a challenging fundraising climate, formal processes are insufficient. SpliceBio's CEO secured their lead Series B investor by starting informal conversations a full year before the official round. This long-term relationship-building establishes trust and allows investors to track execution over time, which is critical when capital is tight.

Vivtex funded its growth and reached profitability not through traditional VC rounds, but by securing around 10 early pharma partnerships. This strategy provided significant non-dilutive revenue, reducing their reliance on investors and giving them more control over their trajectory—a powerful alternative to the typical biotech funding model.

Airway Therapeutics defied convention by raising nearly $100 million from family offices and high-net-worth individuals, not traditional VCs. This strategy funded the company through a pivotal Phase 2B/3 trial, proving that alternative capital sources can successfully fuel late-stage biotech development before institutional rounds.

MRM Health's founder, Sam Possemiers, leveraged his profitable Contract Research Organization (CRO), Prodigest, to finance the entire seed stage of his new biotech venture. Reinvesting proceeds into technology development allowed MRM to de-risk its platform for five years without taking on early-stage dilutive funding.

Arcus navigated its capital-intensive early years by using strategic collaborations to bring in over $1 billion in largely non-dilutive funding. This approach allowed the company to reach late-stage clinical milestones and generate valuable data, bridging the gap to a point where public market investors could see tangible value.

In a tough funding climate, Ovelle successfully raised capital by focusing on investors who personally understood the problem of infertility. This strategy sidesteps the need to educate uninterested parties and instead builds a base of long-term partners who share the company's vision, proving more effective than a broad approach.

MRM Health's fundraising was amplified by a market "wait and see" mentality, which its CEO likens to the Gartner hype cycle. Early failures from first-generation microbiome companies had burned investors, making it difficult for even advanced companies to secure funding, regardless of their positive data.

Even while well-capitalized by its Sanofi partnership, Recludix conducted a Series B financing. The primary motivation was not cash, but to strategically bring investor Eli Lilly onto its cap table, diversifying its powerful network of supporters beyond its existing partner, Sanofi, who is not an equity holder.

A massive, multi-trillion dollar wealth transfer is making family offices more institutionalized and eager to diversify into alternative investments like life sciences. Luba Greenwood points to this as a significant, often overlooked fundraising channel for biotech companies seeking direct investment.